Biotech and Pharma Industry News | BioPharma Dive
WEBBioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Meso Scale Discovery (MSD): An immunoassay platform with …
WEBFeb 22, 2022 · ADVANTAGES. Sensitivity, Range and Ease-of-Use: In comparison to a conventional ELISA, MSD has higher sensitivity (LLOD 0.1-1.4 pg/mL) and a larger dynamic detection range (0.1-10 pg/mL).In addition, MSD has an efficient low volume sampling (1-25 μ L) and minimized matrix effect aiding in simultaneous multiplex detection with high precision. . Furthermore, MSD has simpler protocols, reduced ...
Seagen’s cancer drug succeeds in ‘must-win’ trial
WEBSep 22, 2023 · A combination of cancer drugs from Seagen and Merck & Co. has shown early success in a large clinical trial, results that help confirm the pairing’s ability to treat a wide range of bladder cancer patients. The trial has enrolled around 1,000 participants who have urothelial cancer that’s grown or spread to other parts of the body, and who ...
Two decades and $200 billion: AbbVie’s Humira monopoly nears …
WEBMar 17, 2022 · Its arrival will mark the end of a two-decade run of market exclusivity during which Humira’s maker, AbbVie, has earned nearly $200 billion from sales of the drug. Eight more biosimilars — as copies of biologic drugs are called — are expected to become available over the course of 2023, putting AbbVie under pressure.
Biotech M&A has plateaued. Track the deals that are happening …
WEB3 days ago · Inside the market of emerging biotech. New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously. BioPharma Dive is tracking M&A activity below. The database, which shows drugmaker buyouts that have happened since 2018 and were valued at …
Gilead to lean on Second Genome’s microbiome work in $38M …
WEBApr 6, 2020 · Gilead has struck a deal with Second Genome to identify microbiome-based markers that can indicate whether patients are responding to experimental Gilead medicines. Second Genome, a developer of microbiome therapeutics, will receive $38 million upfront from Gilead through the deal, announced Monday by the companies.
Biotech IPOs are the industry’s lifeblood. Track how they’re …
WEB5 days ago · IPO activity reached a peak in 2021, when more than 100 biotechs priced an initial offering and together raised nearly $15 billion. But that momentum came to a halt as 2021 turned to 2022, and stock prices of newly public companies plummeted amid a sector-wide downturn. The pace of IPOs stalled and, last year, only 19 drugmakers priced initial ...
Lilly wins FDA approval for new kind of diabetes drug
WEBMay 13, 2022 · The Food and Drug Administration on Friday approved Eli Lilly’s diabetes drug Mounjaro, a first-of-its-kind treatment that can help control patients’ blood sugar and, potentially, help them lose weight as well. Mounjaro, also known as tirzepatide, expands Lilly’s diabetes business, which includes insulins as well as other types of therapies.
Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting
WEBJan 9, 2023 · The collective $3.5 billion in upfront consideration is the most pledged to acquisitions to begin J.P. Morgan’s conference since 2019, when Lilly agreed to buy Loxo Oncology for $8 billion. That year’s meeting also came one week after Bristol Myers Squibb’s $74 billion deal for Celgene. Still, none of the three deals disclosed Sunday and ...
The next era of Greater Boston’s biotech boom | BioPharma Dive
WEBNov 22, 2022 · The next era of Greater Boston’s biotech boom. Over the past two decades, the Cambridge area has become a nerve center for biotech in the U.S. But to stay relevant and accessible, the hub is expanding to the suburbs. Published November 22, 2022 • By Karissa Waddick , Shaun Lucas and Julia Himmel. A map of the Kendall Square neighborhood in ...